Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Interferon treatment of human keratinocytes harboring extrachromosomal, persistent HPV-16 plasmid genomes induces de novo viral integration.

Lace MJ, Anson JR, Haugen TH, Dierdorff JM, Turek LP.

Carcinogenesis. 2015 Jan;36(1):151-9. doi: 10.1093/carcin/bgu236. Epub 2014 Nov 21.

PMID:
25416558
2.

Analyzing the Human Papillomavirus (HPV) Life Cycle in Primary Keratinocytes with a Quantitative Colony-Forming Assay.

Lace MJ, Turek LP, Anson JR, Haugen TH.

Curr Protoc Microbiol. 2014 May 1;33:14B.2.1-13. doi: 10.1002/9780471729259.mc14b02s33.

PMID:
24789595
3.

The truncated C-terminal E2 (E2-TR) protein of bovine papillomavirus (BPV) type-1 is a transactivator that modulates transcription in vivo and in vitro in a manner distinct from the E2-TA and E8^E2 gene products.

Lace MJ, Ushikai M, Yamakawa Y, Anson JR, Ishiji T, Turek LP, Haugen TH.

Virology. 2012 Aug 1;429(2):99-111. doi: 10.1016/j.virol.2012.03.020. Epub 2012 May 1.

4.

Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease.

Smith EM, Rubenstein LM, Haugen TH, Pawlita M, Turek LP.

J Oncol. 2012;2012:571862. doi: 10.1155/2012/571862. Epub 2012 Jan 23.

5.

Human papillomavirus serologic follow-up response and relationship to survival in head and neck cancer: a case-comparison study.

Rubenstein LM, Smith EM, Pawlita M, Haugen TH, Hamšíková E, Turek LP.

Infect Agent Cancer. 2011 Jul 8;6:9. doi: 10.1186/1750-9378-6-9.

6.

Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those found in cervical cancers.

Lace MJ, Anson JR, Klussmann JP, Wang DH, Smith EM, Haugen TH, Turek LP.

J Virol. 2011 Feb;85(4):1645-54. doi: 10.1128/JVI.02093-10. Epub 2010 Dec 1.

7.

Tobacco and alcohol use increases the risk of both HPV-associated and HPV-independent head and neck cancers.

Smith EM, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP.

Cancer Causes Control. 2010 Sep;21(9):1369-78. doi: 10.1007/s10552-010-9564-z. Epub 2010 Apr 17.

PMID:
20401530
8.

Evidence for vertical transmission of HPV from mothers to infants.

Smith EM, Parker MA, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP.

Infect Dis Obstet Gynecol. 2010;2010:326369. doi: 10.1155/2010/326369. Epub 2010 Mar 14.

9.

Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer.

Smith EM, Rubenstein LM, Hoffman H, Haugen TH, Turek LP.

Infect Agent Cancer. 2010 Feb 11;5:4. doi: 10.1186/1750-9378-5-4.

10.

Interferon regulatory factor (IRF)-2 activates the HPV-16 E6-E7 promoter in keratinocytes.

Lace MJ, Anson JR, Haugen TH, Turek LP.

Virology. 2010 Apr 10;399(2):270-9. doi: 10.1016/j.virol.2009.12.025. Epub 2010 Feb 2.

11.

Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer.

Smith EM, Pawlita M, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP.

Int J Cancer. 2010 Jul 1;127(1):111-7. doi: 10.1002/ijc.25015.

12.

Human papillomavirus (HPV) type 18 induces extended growth in primary human cervical, tonsillar, or foreskin keratinocytes more effectively than other high-risk mucosal HPVs.

Lace MJ, Anson JR, Klingelhutz AJ, Lee JH, Bossler AD, Haugen TH, Turek LP.

J Virol. 2009 Nov;83(22):11784-94. doi: 10.1128/JVI.01370-09. Epub 2009 Sep 9.

13.

Cellular factor YY1 downregulates the human papillomavirus 16 E6/E7 promoter, P97, in vivo and in vitro from a negative element overlapping the transcription-initiation site.

Lace MJ, Yamakawa Y, Ushikai M, Anson JR, Haugen TH, Turek LP.

J Gen Virol. 2009 Oct;90(Pt 10):2402-12. doi: 10.1099/vir.0.012708-0. Epub 2009 Jun 24.

PMID:
19553391
14.

Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-1.

Lace MJ, Anson JR, Klingelhutz AJ, Harada H, Taniguchi T, Bossler AD, Haugen TH, Turek LP.

Carcinogenesis. 2009 Aug;30(8):1336-44. doi: 10.1093/carcin/bgp150. Epub 2009 Jun 18.

PMID:
19541854
15.

Upstream regulatory region alterations found in human papillomavirus type 16 (HPV-16) isolates from cervical carcinomas increase transcription, ori function, and HPV immortalization capacity in culture.

Lace MJ, Isacson C, Anson JR, Lörincz AT, Wilczynski SP, Haugen TH, Turek LP.

J Virol. 2009 Aug;83(15):7457-66. doi: 10.1128/JVI.00285-09. Epub 2009 May 20.

16.

Cellular factors are required to activate bovine papillomavirus-1 early gene transcription and to establish viral plasmid persistence but are not required for cellular transformation.

Haugen TH, Lace MJ, Ishiji T, Sameshima A, Anson JR, Turek LP.

Virology. 2009 Jun 20;389(1-2):82-90. doi: 10.1016/j.virol.2009.04.002. Epub 2009 May 1.

17.

Functional mapping of the human papillomavirus type 16 E1 cistron.

Lace MJ, Anson JR, Turek LP, Haugen TH.

J Virol. 2008 Nov;82(21):10724-34. doi: 10.1128/JVI.00921-08. Epub 2008 Aug 27.

18.

The E8--E2 gene product of human papillomavirus type 16 represses early transcription and replication but is dispensable for viral plasmid persistence in keratinocytes.

Lace MJ, Anson JR, Thomas GS, Turek LP, Haugen TH.

J Virol. 2008 Nov;82(21):10841-53. doi: 10.1128/JVI.01481-08. Epub 2008 Aug 27.

19.

Does pretreatment seropositivity to human papillomavirus have prognostic significance for head and neck cancers?

Smith EM, Rubenstein LM, Ritchie JM, Lee JH, Haugen TH, Hamsikova E, Turek LP.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2087-96. doi: 10.1158/1055-9965.EPI-08-0054.

20.

Association between p53 and human papillomavirus in head and neck cancer survival.

Smith EM, Wang D, Rubenstein LM, Morris WA, Turek LP, Haugen TH.

Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):421-7. doi: 10.1158/1055-9965.EPI-07-2597.

21.

Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents.

Smith EM, Swarnavel S, Ritchie JM, Wang D, Haugen TH, Turek LP.

Pediatr Infect Dis J. 2007 Sep;26(9):836-40.

PMID:
17721381
22.

Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers.

Pyeon D, Newton MA, Lambert PF, den Boon JA, Sengupta S, Marsit CJ, Woodworth CD, Connor JP, Haugen TH, Smith EM, Kelsey KT, Turek LP, Ahlquist P.

Cancer Res. 2007 May 15;67(10):4605-19.

23.

P16INK4a expression, human papillomavirus, and survival in head and neck cancer.

Smith EM, Wang D, Kim Y, Rubenstein LM, Lee JH, Haugen TH, Turek LP.

Oral Oncol. 2008 Feb;44(2):133-42. Epub 2007 Mar 13.

PMID:
17360226
24.

Human papillomavirus seropositivity and risks of head and neck cancer.

Smith EM, Ritchie JM, Pawlita M, Rubenstein LM, Haugen TH, Turek LP, Hamsikova E.

Int J Cancer. 2007 Feb 15;120(4):825-32.

25.

Cervical keratinocytes containing stably replicating extrachromosomal HPV-16 are refractory to transformation by oncogenic H-Ras.

Berger KL, Barriga F, Lace MJ, Turek LP, Zamba GJ, Domann FE, Lee JH, Klingelhutz AJ.

Virology. 2006 Dec 5-20;356(1-2):68-78. Epub 2006 Aug 30.

26.

Head and neck cancer associated with herpes simplex virus 1 and 2 and other risk factors.

Parker TM, Smith EM, Ritchie JM, Haugen TH, Vonka V, Turek LP, Hamsikova E.

Oral Oncol. 2006 Mar;42(3):288-96.

PMID:
16324878
27.

Alcohol dehydrogenase 3 and risk of squamous cell carcinomas of the head and neck.

Wang D, Ritchie JM, Smith EM, Zhang Z, Turek LP, Haugen TH.

Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):626-32.

28.

HPV prevalence and concordance in the cervix and oral cavity of pregnant women.

Smith EM, Ritchie JM, Yankowitz J, Wang D, Turek LP, Haugen TH.

Infect Dis Obstet Gynecol. 2004 Jun;12(2):45-56.

29.

Persistent HPV infection in postmenopausal age women.

Smith EM, Johnson SR, Ritchie JM, Feddersen D, Wang D, Turek LP, Haugen TH.

Int J Gynaecol Obstet. 2004 Nov;87(2):131-7.

PMID:
15491557
30.

Human papillomavirus in oral exfoliated cells and risk of head and neck cancer.

Smith EM, Ritchie JM, Summersgill KF, Hoffman HT, Wang DH, Haugen TH, Turek LP.

J Natl Cancer Inst. 2004 Mar 17;96(6):449-55.

PMID:
15026470
31.

Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers.

Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH, Wang D, Haugen TH, Turek LP.

Int J Cancer. 2004 Feb 20;108(5):766-72.

32.

Human papillomavirus prevalence and types in newborns and parents: concordance and modes of transmission.

Smith EM, Ritchie JM, Yankowitz J, Swarnavel S, Wang D, Haugen TH, Turek LP.

Sex Transm Dis. 2004 Jan;31(1):57-62.

PMID:
14695959
33.

Prevalence and persistence of human papillomavirus in postmenopausal age women.

Smith EM, Ritchie JM, Levy BT, Zhang W, Wang D, Haugen TH, Turek LP.

Cancer Detect Prev. 2003;27(6):472-80.

PMID:
14642556
34.

Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx.

Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, Klussmann JP, Turek LP, Haugen TH.

Int J Cancer. 2003 Apr 10;104(3):336-44.

35.

Telomerase activation in cervical keratinocytes containing stably replicating human papillomavirus type 16 episomes.

Sprague DL, Phillips SL, Mitchell CJ, Berger KL, Lace M, Turek LP, Klingelhutz AJ.

Virology. 2002 Sep 30;301(2):247-54.

36.

Is use of hormone replacement therapy associated with increased detection of human papillomavirus and potential risk of HPV-related genital cancers?

Smith EM, Levy BT, Ritchie JM, Jia J, Wang D, Haugen TH, Turek LP.

Eur J Cancer Prev. 2002 Jun;11(3):295-305.

PMID:
12131663
37.

Human papillomavirus in the oral cavities of children and adolescents.

Summersgill KF, Smith EM, Levy BT, Allen JM, Haugen TH, Turek LP.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jan;91(1):62-9.

PMID:
11174573
38.

Human papillomavirus and risk of laryngeal cancer.

Smith EM, Summersgill KF, Allen J, Hoffman HT, McCulloch T, Turek LP, Haugen TH.

Ann Otol Rhinol Laryngol. 2000 Nov;109(11):1069-76.

PMID:
11090000
39.

p53 polymorphism, human papillomavirus infection in the oral cavity, and oral cancer.

Summersgill KF, Smith EM, Kirchner HL, Haugen TH, Turek LP.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Sep;90(3):334-9.

PMID:
10982955
40.

Human papillomavirus and risk of oral cancer.

Smith EM, Hoffman HT, Summersgill KS, Kirchner HL, Turek LP, Haugen TH.

Laryngoscope. 1998 Jul;108(7):1098-103.

PMID:
9665264
41.

The frequency of human papillomavirus detection in postmenopausal women on hormone replacement therapy.

Smith EM, Johnson SR, Figuerres EJ, Mendoza M, Fedderson D, Haugen TH, Turek LP.

Gynecol Oncol. 1997 Jun;65(3):441-6.

PMID:
9190973
42.

Simple method for selective amplification of cDNA from a defined promoter.

Bostik P, Turek LP, Haugen TH.

Biotechniques. 1997 Feb;22(2):300-2, 304, 306.

43.

The genetic program of genital human papillomaviruses in infection and cancer.

Turek LP, Smith EM.

Obstet Gynecol Clin North Am. 1996 Dec;23(4):735-58. Review.

PMID:
8989774
44.

Perinatal transmission and maternal risks of human papillomavirus infection.

Smith EM, Johnson SR, Cripe T, Perlman S, McGuinness G, Jiang D, Cripe L, Turek LP.

Cancer Detect Prev. 1995;19(2):196-205.

PMID:
7750107
45.

The structure, function, and regulation of papillomaviral genes in infection and cervical cancer.

Turek LP.

Adv Virus Res. 1994;44:305-56. Review. No abstract available.

PMID:
7817876
46.
47.

Transcriptional enhancer factor (TEF)-1 and its cell-specific co-activator activate human papillomavirus-16 E6 and E7 oncogene transcription in keratinocytes and cervical carcinoma cells.

Ishiji T, Lace MJ, Parkkinen S, Anderson RD, Haugen TH, Cripe TP, Xiao JH, Davidson I, Chambon P, Turek LP.

EMBO J. 1992 Jun;11(6):2271-81.

48.
49.

The association between pregnancy and human papilloma virus prevalence.

Smith EM, Johnson SR, Jiang D, Zaleski S, Lynch CF, Brundage S, Anderson RD, Turek LP.

Cancer Detect Prev. 1991;15(5):397-402.

PMID:
1661203
50.

Comparison of Rous sarcoma virus RNA processing in chicken and mouse fibroblasts: evidence for double-spliced RNA in nonpermissive mouse cells.

Berberich SL, Macias M, Zhang L, Turek LP, Stoltzfus CM.

J Virol. 1990 Sep;64(9):4313-20. Erratum in: J Virol 1990 Dec;64(12):6360.

Supplemental Content

Loading ...
Support Center